A Study of MHB036C for Advanced Solid Tumor
A phase 1/2 trial of MHB036C in advanced solid tumours, run by Minghui Pharmaceutical (Hangzhou) Ltd, active and no longer recruiting.
Overview
A Study of MHB036C for Advanced Solid Tumor is a phase 1/2 interventional study registered as NCT06373406 by Minghui Pharmaceutical (Hangzhou) Ltd, with 200 participants enrolled, started 2023-05-26 and due to reach its primary completion in 2025-12. Interventions recorded: MHB036C.
Similar pages
not linked directly; found by shared links- TrialA Study of MHB036C Combined With MHB039A in Patients With Advanced Breast Cancer or Other Advanced Malignant Solid Tumors
Shares MHB036C, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of MHB036C Combined With Anti-tumor Therapies in Patients With Advanced Lung Cancer
Shares MHB036C, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialInvestigation of a Therapeutic Vaccine (ACIT-1) in Cancer
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPlasmodium Immunotherapy for Advanced Malignant Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialFirst-in-Human Study of ICT01 in Patients With Advanced Cancer
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ASKB589 in Patients With Locally Advanced or Metastatic Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPhase 1/2a Study of MPB-1734 in Patients With Advanced Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.